For years BRAND HEALTH have established successful relationship marketing for the indication Pulmonary Arterial Hypertension (PAH) with continuous long-term communication – and Since the beginning of 2010 with the Product REVATIO® (Sildenafil) from Pfizer as well. The communication provides a highly specialised target group of pulmonologists, cardiologists and rheumatologists with the newest scientific findings in PAH.
Next to the implementation of doctor and patient materials, the two-day Symposium PH UP2DATE is the elementary pillar of the communication strategy. The product-neutral and CME certificate event is accompanied by a comprehensive repertoire of communication measures such as abstracts, sales reports and notifications. On top of this, a Young Investigator award for the research by junior scientific staff takes place.
An efficient team of agency staff and experts of the advisory board accompany the PAH strategies for Pfizer. In particular, BRAND HEALTH encorporates strategies for Orphan diseases and Orphan drugs through market knowledge and its international network, because these indications are globally triggered and communicated.